RxDoctor Payments Data

Nicole Wydra, PA

Medical · Corvallis, ORNPI 1962514836

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 99.0% of the total across 436 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 22 manufacturers reported payments, led by AbbVie at 34.8% of the total. Among medical clinicians in OR with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$7,540in general payments, 2019–2025

Across 436 payments — averaging $17.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Johnson & Johnson$895
  • Lilly USA, LLC$750
  • Pfizer$622
  • Sanofi$469
  • E.r. Squibb & Sons, L.L.C.$293
  • plus $2K from 16 others

What the payments were for

  • Food & beverage$7,46699%
  • Education$731%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$7,540 in reported general payments places this provider in the 95th percentile of 364 medical providers in Oregon.

See all medical providers in Oregon

Medicare billing

Part B allowed, 2024
$102,683
Medicare patients
608
Services billed
1,698

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Skyrizi PenRisankizumab-Rzaa19$410,138
Dupixent PenDupilumab35$149,255
SiliqBrodalumab12$54,372
Tacrolimus52$5,293
Clobetasol Propionate107$4,461
Fluorouracil36$2,449
Ketoconazole37$634
Ciclopirox30$601
Triamcinolone Acetonide45$583
Clindamycin Phosphate13$488
Fluocinonide22$432
Hydroxychloroquine Sulfate19$399
ValacyclovirValacyclovir Hcl11$338
Doxycycline Monohydrate16$251
Doxycycline Hyclate16$224

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Ortho Dermatologics, A Division Of Bausch Health US, LLCSiliq$36$54,37212 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 364 medical providers in Oregon.

Other medical in Corvallis

See the full list for Oregon

Where these figures come from

Is this you, or does something look wrong? →